Efficacy of novel rifamycin derivatives against rifamycin-sensitive and -resistant Staphylococcus aureus isolates in murine models of infection

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 11, 2006, Pages 3658-3664

  Rothstein, David M ^a   Farquhar, Ronald S ^a,d   Sirokman, Klari ^b,c   Sondergaard, Karen L ^b,c   Hazlett, Charles ^b,c,e   Doye, Angelia A ^b,c   Gwathmey, Judith K ^b,c   Mullin, Steve ^a,f   Van Duzer, John ^a   Murphy, Christopher K ^a  

^a ActivBiotics Inc   (United States)

^b Gwathmey Inc   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d CHARLES RIVER LABORATORIES   (United States)

^e Infectious Disease ^*  (United States)

^f NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABI 0038; ABI 0039; ABI 0043; ABI 0045; ABI 0046; ABI 0055; ABI 0063; ABI 0094; ABI 0204; ABI 0269; ABI 0273; ABI 0279; ABI 0280; ABI 0299; ABI 0302; ABI 0306; ABI 0322; ABI 0338; ABI 0354; ABI 0361; ABI 0370; ABI 0375; ABI 0376; ABI 0418; ABI 0420; ABI 1131; PLACEBO; RIFALAZIL; RIFAMPICIN; RIFAMYCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM MUTANT; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG STRUCTURE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; SEPTICEMIA; STAPHYLOCOCCUS AUREUS;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG RESISTANCE, BACTERIAL; MICE; MICROBIAL SENSITIVITY TESTS; MUSCLE, SKELETAL; MUTATION; NEUTROPENIA; RIFAMYCINS; SEPSIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33750579749     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01087-05     Document Type: Article

References (26)

1. Akada, J. K., M. Shirai, K. Fujii, K. Okita, and T. Nakazawa. 1999. In vitro anti-Helicobacter pylori activities of new rifamycin derivatives, KRM-1648 and KRM-1657. Antimicrob. Agents Chemother. 43:1072-1076.
2. Anton, P. M., M. O'Brien, E. Kokkotou, B. Eisenstein, A. Michaelis, D. Rothstein, S. Paraschos, C. P. Kelly, and C. Pothoulakis. 2004. Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters. Antimicrob. Agents Chemother. 48:3975-3979.
3. Aubry-Damon, H., M. Galimand, G. Gerfaaud, and P. Courvalin. 2002. rpoB mutation conferring rifampin resistance in Streptococcus pyogenes. Antimicrob. Agents Chemother. 46:1571-1573.
4. Cleeland, R., and E. Squires. 1991. Evaluation of new antimicrobials in vitro and in experimental animal infections, p. 752-783. In V. Lorian (ed.), Antibiotics in laboratory medicine, 3rd ed. Williams and Wilkins Co., Baltimore, Md.
5. Dietze, R., L. Teixeira, L. M. Rocha, M. Palaci, J. L. Johnson, C. Wells, L. Rose, K. Eisenach, and J. J. Ellner. 2001. Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis. Antimicrob. Agents Chemother. 45:1972-1976.
6. Fujii, K., H. Saito, H. Tomioka, T. Mae, and K. Hosoe. 1995. Mechanism of action of antimycobacterial activity of the new benzoxazinorifamycin KRM-1648. Antimicrob. Agents Chemother. 39:1489-1492.
7. Fujii, K., A. Tsuji, S. Miyazaki, K. Yamaguchi, and S. Goto. 1994. In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives. Antimicrob. Agents Chemother. 38:1118-1122.
8. Hirata, T., H. Saito, H. Tomioka, K. Sato, J. Jidoi, K. Hosoe, and T. Hidafca. 1995. In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 39:2295-2303.
9. Kuo, C.-C., J. T. Grayston, T. Hidaka, and L. M. Rose. 1997. A comparison of the inyitro sensitivity of Chlamydia pneumoniae to the macrolides and the new benzoxazinorifamycin, KRM-1648, p. 317-321. In S. H. Zinner, L. S. Young, J. F. Acar, and H. C. Neu (ed.), Expanding indications for the new macrolides, azalides, and streptogramins. Infectious Disease and Therapy Series, vol. 21. Marcel Dekker, New York, N.Y.
10. Leggett, J. E., S. Ebert, B. Fantin, and W. A. Craig. 1990. Comparative dose-effect relations at several dosing intervals for β-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. Scand. J. Infect. Dis. Suppl. 74:179-184.
11. Louie, A., P. Kaw, W. Liu, N. Jumbe, M. H. Miller, and G. L. Drusano. 2001. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob. Agents Chemother. 45:845-851.
12. McCabe, W. R., and V. Lorian. 1968. Comparison of the antibacterial activity of rifampicin and other antibiotics. Am. J. Med. Sci. 256:255-265.
13. Moghazeh, S. L., X. Pan, T. Arain, C. K. Stover, J. M. Musser, and B. N. Kreiswirth. 1996. Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrob. Agents Chemother. 40:2655-2657.
14. Mullin, S., D. M. Rothstein, and C. K. Murphy. 2006. Activity of novel benzoxazinorifamycins against rifamycin-resistant Streptococcus pyogenes. Antimicrob. Agents Chemother. 50:1908-1909.
15. Murphy, C. K., S. Mullin, M. S. Osburne, J. van Duzer, J. Siedlecki, X. Yu, K. Kerstein, M. Cynamon, and D. M. Rothstein. 2006. In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 50:27-34.
16. Niemi, M., J. T. Backman, M. F. Fromm, P. J. Neuvonen, and K. T. Kivisto. 2003. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin. Pharmacokinet. 42:819-850.
17. Park, Y. K., B. J. Kim, S. Ryu, Y. H. Kook, Y. K. Choe, G. H. Bai, and S. J. Kim. 2002. Cross-resistance between rifampicin and KRM-1648 is associated with specific rpoB alleles in Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 6:166-170.
18. Roblin, P. M., T. Reznik, A. Kutlin, and M. R. Hammerschlag. 2003. In vitro activities of rifamycin derivatives ABI-1648 (rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae. Antimicrob. Agents Chemother. 47:1135-1136.
19. Rothstein, D. M., A. D. Hartman, M. H. Cynamon, and B. I. Eisenstein. 2003. Development potential of rifalazil. Expert Opin. Investig. Drugs 12:255-271.
20. Shoen, C. M., M. S. DeStefano, and M. H. Cynamon. 2000. Durable cure for tuberculosis: rifalazil in combination with isoniazid in a murine model of Mycobacterium tuberculosis infection. Clin. Infect. Dis. 30(Suppl. 3):S288-S290.
21. Suchland, R. J., A. Bourillon, E. Denamur, W. E. Stamm, and D. M. Rothstein. 2005. Rifampin-resistant RNA polymerase mutants of Chlamydia trachomatis remain susceptible to the ansamycin rifalazil. Antimicrob. Agents Chemother. 49:1120-1126.
22. Suchland, R. J., K. Brown, D. M. Rothstein, and W. E. Stamm. 2006. Rifalazil pretreatment of mammalian cell cultures prevents subsequent Chlamydia infection. Antimicrob. Agents Chemother. 50:439-444.
23. Wichelhaus, T., V. Schafer, V. Brade, and B. Boddinghaus. 2001. Differential effect of rpoB mutations on antibacterial activities of rifampicin and KRM-1648 against Staphylococcus aureus. J. Antimicrob. Chemother. 47:153-156.
24. Wichelhaus, T. A., V. Schafer, V. Brade, and B. Boddinghaus. 1999. Molecular characterization of rpoB mutations conferring cross-resistance to rifamycins on methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 43:2813-2816.
25. Williams, D. L., L. Spring, L. Collins, L. P. Miller, L. B. Heifets, P. R. Gangadharam, and T. P. Gillis. 1998. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 42:1853-1857.
26. Yang, B., H. Koga, H. Ohno, K. Ogawa, M. Fukuda, Y. Hirakata, S. Maesaki, K. Tomono, T. Tashiro, and S. Kohno. 1998. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. J. Antimicrob. Chemother. 42:621-628.